Abstract:The effects of the second‐generation antipsychotic risperidone (RIS) on reactive oxygen species (ROS) and microglia were analyzed using a mouse ketamine (KET) model of schizophrenia. Compared to KET‐treated mice, KET/RIS‐treated mice exhibited lower gene expression of the ROS‐generating enzyme (Nox2), and higher expression of antioxidant enzymes (Ho‐1 and Gclc). Three types of microglia were defined by hierarchical cluster analysis: resting‐ramified (type I) in control mice, moderately ramified (type II) in KET‐treated mice, and hyper‐ramified (type III) in KET/RIS‐treated mice. In vitro ROS assay showed that RIS reduced the production of microglial ROS induced by KET. Notably, antioxidant compounds (N‐Acetyl‐L‐cysteine [NAC] and GSK 2795039 [GSK]) alleviated schizophrenia‐like behaviors induced by KET, suggesting a promising direction for the development of novel treatments for schizophrenia. Recent studies have highlighted the potential involvement of reactive oxygen species (ROS) and microglia, a major source of ROS, in the pathophysiology of schizophrenia. In our study, we explored how the second‐generation antipsychotic risperidone (RIS) affects ROS regulation and microglial activation in the hippocampus using a mouse ketamine (KET) model of schizophrenia. KET administration resulted in schizophrenia‐like behaviors in male C57BL/6J mice, such as impaired prepulse inhibition (PPI) of the acoustic startle response and hyper‐locomotion. These behaviors were mitigated by RIS. We found that the gene expression level of an enzyme responsible for ROS production (Nox2), which is primarily associated with activated microglia, was lower in KET/RIS‐treated mice than in KET‐treated mice. Conversely, the levels of antioxidant enzymes (Ho‐1 and Gclc) were higher in KET/RIS‐treated mice. The microglial density in the hippocampus was increased in KET‐treated mice, which was counteracted by RIS. Hierarchical cluster analysis revealed three morphological subtypes of microglia. In control mice, most microglia were resting‐ramified (type I, 89.7%). KET administration shifted the microglial composition to moderately ramified (type II, 44.4%) and hyper‐ramified (type III, 25.0%). In KET/RIS‐treated mice, type II decreased to 32.0%, while type III increased to 34.0%. An in vitro ROS assay showed that KET increased ROS production in dissociated hippocampal microglia, and this effect was mitigated by RIS. Furthermore, we discovered that a NOX2 inhibitor could counteract KET‐induced behavioral deficits. These findings suggest that pharmacological inhibition of ROS production by RIS may play a crucial role in ameliorating schizophrenia‐related symptoms. Moreover, modulating microglial activation to regulate ROS production has emerged as a novel avenue for developing innovative treatments for schizophrenia.

Minocycline and Risperidone Prevent Microglia Activation and Rescue Behavioral Deficits Induced by Neonatal Intrahippocampal Injection of Lipopolysaccharide in Rats.

The efficacy of minocycline on behavioral deficits and microglial activation induced by intrahippocampal injection of lipopolysaccharide

Neonatal intrahippocampal injection of lipopolysaccharide induces deficits in social behavior and prepulse inhibition and microglial activation in rats: Implication for a new schizophrenia animal model.

Minocycline Alleviates Behavioral Deficits and Inhibits Microglial Activation Induced by Intrahippocampal Administration of Granulocyte-Macrophage Colony-Stimulating Factor in Adult Rats.

Minocycline alleviates behavioral deficits and inhibits microglial activation in the offspring of pregnant mice after administration of polyriboinosinic-polyribocytidilic acid.

Minocycline Protects Against Lipopolysaccharide-Induced Cognitive Impairment in Mice

Minocycline protects against lipopolysaccharide-induced glial cells activation and oxidative stress damage in the medial prefrontal cortex (mPFC) of the rat

Pretreatment with minocycline improves neurogenesis and behavior performance after midazolam exposure in neonatal rats.

Depletion of Microglia with PLX3397 Attenuates MK-801-induced Hyperactivity Associated with Regulating Inflammation-Related Genes in the Brain

Modulating microglia activation prevents maternal immune activation induced schizophrenia-relevant behavior phenotypes via arginase 1 in the dentate gyrus

Inhibition of microglial activation by minocycline reduced preoligodendrocyte injury in a neonatal rat brain slice model

The Effect of Minocycline on Amelioration of Cognitive Deficits and Pro-Inflammatory Cytokines Levels in Patients with Schizophrenia.

Down-Regulation of Hippocampal Genes Regulating Dopaminergic, GABAergic, and Glutamatergic Function Following Combined Neonatal Phencyclidine and Post-Weaning Social Isolation of Rats as a Neurodevelopmental Model for Schizophrenia

Minocycline Protects Against Lipopolysaccharide-Induced Cognitive Impairment and Oxidative Stress: Possible Role of the CREB-BDNF Signaling Pathway

Minocycline alleviates depression-like symptoms by rescuing decrease in neurogenesis in dorsal hippocampus via blocking microglia activation/phagocytosis

Intervention effects of minocycline on nigral glial activation and of dopamine neuronal survival in the lactacystin rat model of Parkinson's disease

Prenatal Immune Challenge Differentiates the Effect of Aripiprazole and Risperidone on CD200–CD200R and CX3CL1–CX3CR1 Dyads and Microglial Polarization: A Study in Organotypic Cortical Cultures

Microglia inversely regulate the level of perineuronal nets with the treatment of lipopolysaccharide and valproic acid

Early-Life Social Isolation-Induced Depressive-Like Behavior in Rats Results in Microglial Activation and Neuronal Histone Methylation That Are Mitigated by Minocycline.

Inhibition of reactive oxygen species production accompanying alternatively activated microglia by risperidone in a mouse ketamine model of schizophrenia

Minocycline Attenuates Neonatal Germinal-Matrix-Hemorrhage-Induced Neuroinflammation and Brain Edema by Activating Cannabinoid Receptor 2